Drugs / Latilactobacillus sakei
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04938908 | Jul 2021 → Jun 2022 | dry eye syndrome | Shiraz University of Medical Sciences | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-30 | AB Biotics, SA | Results Postbiotic Shown to Improve Skin Elasticity and Hydration in New Clinical Study ab-biotics.com ↗
A newly published clinical study has found that the postbiotic strain Latilactobacillus sakei KABP®‑065, developed by AB‑BIOTICS, can help support skin elasticity and hydration in healthy women aged 30 to 50. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-30 | AB Biotics, SA | Postbiotic Shown to Improve Skin Elasticity and Hydration in New Clinical Study ab-biotics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Latilactobacillus sakei | “This study aimed to evaluate the efficacy and safety of Latilactobacillus sakei (L. sakei) either as an ophthalmic bacterial lysate (drops, no live organism) or as an oral...” PMID 37256485 ↗ May 2023 |
| Known as | L. sakei | “This study aimed to evaluate the efficacy and safety of Latilactobacillus sakei (L. sakei) either as an ophthalmic bacterial lysate (drops, no live organism) or as an oral...” PMID 37256485 ↗ May 2023 |
| Modality | Other / unclassified | “ophthalmic bacterial lysate” PMID 37256485 ↗ May 2023 |